The lot number on the vial matches the certificate, which at least rules out the easy problem.
I would like to know the limits of what can be inferred from this.
What I am trying to avoid is over-reading a single result, which I have done before.
What would I need in addition before this supported a decision?
The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.
The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
If testing multiple vials, state how many you tested and why you chose those vials.
edited 3 Jul 2025 by nadia_kowalczyk — added a caveat about sampling
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsTwo vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.
Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 3 Jul 2025 by charge_state_3 — corrected a unit error in the worked example
Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.
For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.
Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
I would treat a "complies with" statement without sampling details as a claim rather than as evidence.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.
The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.